Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1996-12-9
|
| pubmed:abstractText |
We investigated the in vitro antitumor activity of monocytes derived from autologous bone marrow transplanted (ABMT) patients treated in vivo with granulocyte-macrophage colony-stimulating factor (GM-CSF). Thirty-four patients (17 female, 17 male), median age 42 (range 3-57) years, were enrolled in the study. Fourteen patients were diagnosed with non-Hodgkin's lymphoma (NHL), eight with Hodgkin's disease (HD), nine with breast cancer and three with neuroblastoma. Six patients who did not receive GM-CSF post-ABMT served as controls. We assessed cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), expression of the activation antigen CD16, and cytokine production by an enriched population of monocytes (> 90% CD+14) pre-, during and post-GM-CSF administration. Within the group of patients receiving treatment, ADCC was significantly higher during in vivo GM-CSF administration than post-therapy (P < 0.05) and in 50% of these patients, ADCC increased during in vivo GM-CSF administration over pretreatment values. In addition, in vivo GM-CSF administration caused the monocytes to secrete elevated levels of tumor necrosis factor-alpha (TNF-alpha) and GM-CSF (P < 0.05). We conclude that GM-CSF augments monocyte-mediated cytotoxicity post-ABMT, and therefore may have a role in controlling minimal residual disease post-transplant.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0145-2126
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
637-43
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8913316-Adolescent,
pubmed-meshheading:8913316-Adult,
pubmed-meshheading:8913316-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:8913316-Bone Marrow Transplantation,
pubmed-meshheading:8913316-Breast Neoplasms,
pubmed-meshheading:8913316-Child,
pubmed-meshheading:8913316-Child, Preschool,
pubmed-meshheading:8913316-Female,
pubmed-meshheading:8913316-Follow-Up Studies,
pubmed-meshheading:8913316-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:8913316-Hodgkin Disease,
pubmed-meshheading:8913316-Humans,
pubmed-meshheading:8913316-Lymphoma,
pubmed-meshheading:8913316-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8913316-Male,
pubmed-meshheading:8913316-Middle Aged,
pubmed-meshheading:8913316-Monocytes,
pubmed-meshheading:8913316-Neuroblastoma,
pubmed-meshheading:8913316-Transplantation Conditioning,
pubmed-meshheading:8913316-Treatment Outcome,
pubmed-meshheading:8913316-Tumor Necrosis Factor-alpha
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation.
|
| pubmed:affiliation |
Department of Bone Marrow Transplantation and Oncology, Hadassah University Hospital, Jerusalem, Israel.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|